Stem Cell Beta-Cell Differentiation with Epigenetic Modifiers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating pancreatic β-cells from stem cells are limited by the scarcity and quality of donor islets, necessitating the development of efficient strategies to produce a large supply of functional β-cells for diabetes treatment.
Innovation Solution
The use of epigenetic modifying compounds, such as histone methyltransferase and deacetylase inhibitors, in conjunction with specific signaling pathway modulators, to enhance the differentiation of pancreatic progenitor cells into endocrine cells with increased CHGA+ and NKX6.1+ cells and reduced VMAT or Cdx2 expression, resulting in functional β-cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If epigenetic modifying compounds are used to enhance differentiation, then the proportion of functional β-cells increases, but the complexity of the differentiation process increases
Solution Approach 1:
The patent applies epigenetic modifying compounds that change the epigenetic parameters (histone methylation, acetylation) of pancreatic progenitor cells to enhance their differentiation into functional β-cells. This parameter change approach directly increases the proportion of CHGA+ and NKX6.1+ cells while reducing VMAT or Cdx2 expression, resolving the contradiction by modifying cellular parameters rather than increasing process complexity
Solution Approach 2:
The patent uses epigenetic modifying compounds as intermediary substances to mediate the differentiation process. These compounds (histone methyltransferase inhibitors, deacetylase inhibitors) act as mediators between the progenitor cells and the desired β-cell phenotype, enabling enhanced differentiation without requiring complex procedural interventions
2Reliability
If donor islets are used for transplantation, then functional β-cells are provided, but the supply is limited by scarcity and quality
Solution Approach 1:
The patent creates copies of functional β-cells by differentiating pancreatic progenitor cells into endocrine cells with enhanced β-cell characteristics. Instead of relying on scarce donor islets, the method generates multiple copies of functional β-cells through controlled differentiation processes using epigenetic modifying compounds, thereby increasing the available supply while maintaining functional reliability
Solution Approach 2:
The patent enables pancreatic progenitor cells to self-differentiate into functional β-cells through the action of epigenetic modifying compounds. The cells perform their own differentiation and maturation process, generating functional β-cells without requiring donor islets, thus making the system self-sufficient and eliminating the limitation of donor availability
Data Source
AI summary
Disclosed herein are compositions and methods of enhancing stem cell differentiation into beta cells with use of one or more epigenetic modification compounds. The present disclosure also relates to compositions and methods of sorting and enriching the differentiated beta cells. The present disclosure also relates to compositions and methods of irradiating cell population for reducing proliferation.